Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 2
Submit an article Journal homepage
61
Views
13
CrossRef citations to date
0
Altmetric
Review

Thalidomide analogues: derivatives of an orphan drug with diverse biological activity

Frederick A Luzzio Department of Chemistry, University of Louisville, 2320 South Brook Street, Louisville, Kentucky 40292, USA. [email protected]
&
William D Figg Pharmacology Section, National Cancer Institute, 10/5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA. [email protected]
Pages 215-229 | Published online: 02 Mar 2005

Bibliography

  • SERVICE RF: Can thalidomide be rehabilitated? Science (1995) 269:1340.
  • RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Ann. Rev Med. (2002) 53:629–657.
  • MARRIOTT JB, MULLER G, STIRLING D et al.: Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin. Biol. Ther. (2001) 1:675–682.
  • MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immunol. Today(1999) 20:538–540.
  • RAJE N, ANDERSON K: Thalidomide - a revival story. N Engl. J. Med. (1999) 341:1606–1609.
  • HALES BF: Thalidomide on a comeback trail. Nat. Med. (1999) 5:489–490.
  • FICKENTSCHER K, KIRFEL A, WILL G et al.: Stereochemical properties and teratogenic activity of some tetrahydrophthalimides. Mol. Pharmacol (1977) 13:133–141.
  • HELM F, FRANKUS E, FRIDERICHS E et al.: Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide Arzneim. Forsch. (1981) 31:941–949.
  • SHESKIN J: Thalidomide in the treatment of the lepra reaction. Clin. Pharmacol Ther. (1965) 6:303.
  • SHESKIN J: The treatment of the lepra reaction in lepromatous leprosy. Fifteen years experience with thalidomide. Int. J. Dermatol (1980) 6:318–322.
  • SAMPAIO EP, SARNO EN, GALILY R et al.: Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes J. Exp. Med. (1991) 173:699–703.
  • MULLER GW, CORRAL LG, SHIRE MG et al.: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity J. Med. Chem. (1996) 39:3238–3240.
  • CORRAL LG, MULLER GW, MOREIRA AL et a/.: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor-a inhibitory activity. Molecular. Med. (1996) 2:506–515.
  • D'AMATO RJ, LOUGHNAN MS, FLYNN E et al.: Thalidomide is an inhibitor of angiogenesis. Proc . Nati Acad. ScL USA (1994) 91:4082–4085.
  • REIST M, CARRUPT P-A, FRANCOTTE E et al.: Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem . Res. Toxicol (1998) 11:1521–1528.
  • MULLER GW, KONNECKE WE, SMITH AM et al: A concise two-step synthesis of thalidomide. Org . Proc. Res. Dev. (1999) 3:139–140.
  • SUZUKI E, SHIBATA N: Three-step synthesis of (A and (5)-thalidomides from ornithine. Enantiomer (2001) 6:275–279.
  • ROBINS, ZHU J, GALONS H et al: A convenient asymmetric synthesis of thalidomide. Tetrahedron Asymmetry (1995) 6:1249–1252.
  • ISHIMURA K, HASHIMOTO Y, IWASAKI S: The (3)-form of a-methyl-N-(a)-phthalimidoglutarimide, but not its (M-form, enhanced phorbol ester-induced tumor necrosis factor-a production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull. (1994) 42:1157–1159.
  • LUZZIO FA, MAYOROV AV, FIGG WD:Thalidomide metabolites. Part 1: derivatives of (+) 2 (Nphthalimido)-y-hydroxyglutamic acid. Tetrahedron Lett. (2000) 41:2275–2278.
  • LUZZIO FA, THOMAS EM, FIGG WD: Thalidomide metabolites and analogues. Part 2: cyclic derivatives of 2-N-phthalimido-2S, 3S(3-hydroxy) ornithine. Tetrahedron Lett. (2000) 41:7151–7155.
  • LUZZIO FA, ZACHERL DP, FIGG WD A facile scheme for phthalimide-phthalimidine conversion. Tetrahedron Lett. (1999) 40:2087–2090.
  • LUZZIO FA, MAYOROV AV, NG SSW et al.: Thalidomide metabolites and analogues. Part 3. Synthesis and antiangiogenic activity of the teratogenic and TNF-a-modulatory thalidomide analogue 2- (2,6-dioxopiperidine-3-yflphthalimidine. I Med. Chem. (2003) 46:3793–3799.
  • KNOCHE B, BLASCHKE G: Stereoselectivity of the M vitro metabolism of thalidomide. Chirality (1994) 6:221–224.
  • ERICSSON T, BJORKMAN S, ROTH B et al.: Hydroxylated metabolites of thalidomide: formation M vitro and in vivo in man. Pharm. Pharmacol (1998) 50:1409–1416.
  • CZEJKA MJ, KOCH HP: Determination of thalidomide and its major metabolites by high performance liquid chromatography. .1. Chromatog. (1987) 413:181–187.
  • KIM KJ, LI B, WINER J et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth M vivo. Nature (1993) 362:841–844.
  • FOLKMAN J: Tumor angiogenesis: a possible control point in tumor growth Ann. Intern. Med. (1975) 82:96–100.
  • TEUBERT U, ZWINGENBERGER K, WNENDT S et al: 5€-Substituted thalidomide analogs as modulators of TNF-a. Arkiv. Pharmazie (1998) 331:7–12.
  • NG SS, GUTSCHOW M, WEISS M et al: Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. (2003) 63:3189–3194.
  • NICOSIA RF, OTTINETTI A: A growth of microvessels in serum-free matrix culture of rat aorta. Lab. Invest. (1990) 63:115–122.
  • BAUER KS, DIXON SC, FIGG WD: Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem. Pharmacol (1998) 55:1827–1834.
  • MULLER GW, CHEN R, HUANG S-Y et al.: Amino-substitutedthalidomide analogs: potent inhibitors of TNF-a production. Bioorg. Med. Chem. Lett. (1999) 9:1625–1630.
  • DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br. Cancer (2002) 87:1155–1172.
  • DREDGE K, DALGLEISH AG, MARRIOTT JB: Thalidomide analogs as emerging anticancer drugs. Anti-Cancer Drugs (2003) 14:331–335.
  • MAKONKAWKEYOON S, LIMSON -PROBRE RNR, MOREIRA AL et al.: Thalidomide inhibits the replication of human immunodeficiency virus Type 1. Proc. Nati Acad. ScL USA (1993) 90:5974–5978.
  • AGLE LMA, ROSENKRANZ M, LEHMAN TJA: Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). Expert Opin. Investig. Drugs (2003) 12:19–28.
  • VOGELSANG GB, FARMER ER, HESS AD et al: Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl.' Med. (1992) 326:1055–1058.
  • TEO SK, CHEN Y, MULLER GW et al:Chiral inversion of the second generation IMiD CC-4047 (ACTIMID) in human plasma and phosphate-buffered saline. Chirality (2003) 15:348–351.
  • LA MAESTRA L, ZANINONI A, MARRIOTT JB et al.: The thalidomide analogue CC-3052 inhibits HIV and tumor necrosis factor-alpha (TNF-a) expression in acutely and chronically infected cells M vitro. Gin. Exp. Immunol (2000) 119:123–129.
  • MARRIOTT JB, WESTBY M, COOKSONS et al: CC-3052: a water-soluble analogue of thalidomide and potent inhibitor of activation-induced TNF-a production. Immunol (1998) 161:4236–4243.
  • ZHU X, GIORDANO T, YU Q-S et al.:Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-a activity. Med. Chem. (2003) 46:5222–5229.
  • HASLETT PAJ, CORRALL LG, ALBERT M et al.: Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Exp. Med. (1998) 187:1885–1892.
  • SHANNON EJ, SANDOVAL FG: Thalidomide can co-stimulate or suppress CD4+ cells' ability to incorporate [3H] thymidine-dependence on the primary stimulant. Int. Immunopharm. (2002) 2:1143–1153.
  • MARRIOTT JB, CLARK IA, DREDGE K. et al.: Thalidomide and its analogues have distinct and opposing effects on TNF-a and TNER2 during co-stimulation of both CD4+ and CD8+ T cells. Clin. Exp. Immunol (2002) 130:75–84.
  • BEKKER L-G, HASLETT P, MAARTENS G et al.: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus Type I and tuberculosis. Infect. Dis. (2000) 181:954–965.
  • GORI A, ROSSI MC, TRABATTONI Det al.: Tumor necrosis factor-a increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus co-infection. Infect . Dis. (2000) 182:639–640.
  • WOLKENSTEIN P, LATARJET J, ROUJEAU J-C et al: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 352:1–4.
  • JACOBSON JM, GREENSPAN JS, SPRITZLER J et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl. I Med. (1997) 336:1487–1493.
  • SCHAFER PH, GANDI AK, LOVELAND MA et al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. I Pharm. Exp. The]: (2003) 305:1222–1232.
  • DREDGE K, MARRIOTT JB, TODRYK SM et al.: Protective antitumor activity induced by a co-stimulatory thalidomide analogue in conjunction with whole tumor cell vaccination is mediated by increased T1-type immunity. Immunol (2002) 168:4914–4918.
  • NOGUCHI T, SHIMAZAWA R, NAGASAWA K et al.: Thalidomide and its analogues as cyclooxygenase inhibitors Bioorg. Med. Chem. Lett. (2002) 12:1043–1046.
  • FUJITA J, MESTRE JR, ZELDIS JB et al.: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349–3355.
  • ERIKSSON T, BJORKMAN S, HOGLUND P: Clinical pharmacology of thalidomide. Ear' Clin. Pharmacol (2001) 57:365–376.
  • RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide in multiple myeloma. Biomed. Phamacother. (2002) 56:115–128.
  • SCHEY S, JONES R, RAJ K et al: A Phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide in relapsed/refractory multiple myeloma. Exp. Hematol (2002) 30(Suppl.):248.
  • MARRIOTT JB, CLARKE IA, DREDGE K et al: Thalidomide analogue CC-5013 is safe and well tolerated by patients with end-stage cancer and shows evidence of clinical responses and extensive immune activation. Br. Cancer (2002) 86(Suppl.):S26.
  • HIDESHIMA T, CHAUAN D, SHIMA Y et al.: Thalidomide and its analogues overcome drug resistance of multiple myeloma cells to conventional therapy. Blood (2000) 96:2943–2950.
  • LENTZSH S, ROGERS M, LEBLANC R et al.: 3-Amino-phthal-imido-glutarimide (S-3APG) inhibits angiogenesis and growth in drug resistant multiple myeloma in vivo. Blood (2001) 98\(Part 1):1976.
  • MESS ORI A, TRIPPOLI S, SANTARLASCI B: Pharmacotherapy of multiple myeloma: an economic perspective. Expert Opin. Pharmacother. (2003) 4:515–524.
  • SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple melanoma. N Engl.' Med. (1999) 341:1565–1571.
  • RICHARDSON PG, SCHLOSSMAN R, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063–3067.
  • LU J, PALMER BD, KESTELL P et al.: Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res. (2003) 9:1680–1688.
  • SORBERA LA, CASTANER J, BAYES M: CC-5013. Treatment of multiple myeloma, treatment of melanoma, treatment of myelodysplastic syndrome, angiogensis inhibitor, TNF-a production inhibitor. Drugs Fut. (2003) 28:425–431.
  • LIST AF, KURTIN SF, GLINSMANN -GIBSON BJ: High erythropoietic remitting activity of the immunomodulatory thalidomide analogue, CC-5013, in patients with myelodysplastic syndrome (MDS). Blood(2002) 100: (Part 1)353.
  • LIST AF, KURTIN S, GLINSMANN -GIGSON B: Efficacy and safety of CC-5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS). Blood (2003) 102\(Part1):641.

Websites

  • http://www.clinicaltrials.gov National Institutes of Health. Clinical Trials Website. 8 December 2003.
  • http://www.celgene.com Celgene Corporation Website. 8 December 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.